Molecular Psychiatry
November 21, 2017
Ning Yao, Olga Skiteva, Xue-Qin Zhang et al.
123 citations
Low doses of ketamine trigger rapid and lasting antidepressant effects after one injection in treatment-resistant patients with major depressive disorder. Modulation of AMPA receptors (AMPARs) in the hippocampus and prefrontal cortex is suggested to mediate the antidepressant action of ketamine and of one of its metabolites (2R,6R)-hydroxynorketamine ((2R,6R)-HNK). We have examined whether...
Scientific Reports
November 17, 2017
Katja Weckmann, Michael J Deery, Julie A Howard et al.
Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently available antidepressants (ADs) show full remission. Moreover, about one third of the patients suffering from MDD does not respond to conventional ADs and develop treatment-resistant depression (TRD). Ketamine, a non-competitive, voltage-dependent N-Methyl-D-aspartate receptor (NMDAR) antagonist, has been...
Current Psychiatry Reports
November 15, 2017
Carolina Medeiros da Frota Ribeiro, Patricio Riva-Posse
The purpose of this paper is to provide a review of the use of ketamine as an antidepressant for treatment-resistant depression (TRD) in the geriatric population. Available treatment options for late-life treatment-resistant depression are limited and include electroconvulsive therapy and transcranial magnetic stimulation as well as possible pharmacologic augmentation. Ketamine has been shown...
The International Journal of Neuropsychopharmacology
November 15, 2017
Kai Zhang, Chao Dong, Yuko Fujita et al.
48 citations
Background: Previous reports suggest that 5-hydroxytryptamine might play a role in the antidepressant actions of (R,S)-ketamine. However, its role in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, is unknown. This study was conducted to examine whether 5-hydroxytryptamine depletion affects the antidepressant actions of (R)-ketamine in a chronic social defeat...
The International Journal of Neuropsychopharmacology
November 14, 2017
Yukihiko Shirayama, Kenji Hashimoto
113 citations
Background: (R)-Ketamine exhibits rapid and sustained antidepressant effects in animal models of depression. It is stereoselectively metabolized to (R)-norketamine and subsequently to (2R,6R)-hydroxynorketamine in the liver. The metabolism of ketamine to hydroxynorketamine was recently demonstrated to be essential for ketamine's antidepressant actions. However, no study has compared the...
Scientific Reports
November 10, 2017
Youge Qu, Chun Yang, Qian Ren et al.
126 citations
Accumulating evidence suggests a key role of the gut-microbiota-brain axis in the antidepressant actions of certain compounds. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, showed rapid and sustained antidepressant effects in treatment-resistant depressed patients. In contrast, another NMDAR antagonist, lanicemine, did not exhibit antidepressant effects in such patients....
Journal of Pharmacological Sciences
November 1, 2017
Soichiro Ide, Yuiko Ikekubo, Masayoshi Mishina et al.
44 citations
We investigated the rapid and sustained antidepressant effects of enantiomers of ketamine in N-methyl-d-aspartate (NMDA) receptor GluN2D subunit knockout (GluN2D-KO) mice. Intraperitoneal administration of ketamine or its enantiomers 10 min before the tail-suspension test exerted significant antidepressant effects on restraint stress-induced depression in both wildtype and GluN2D-KO mice. The...
Magnetic resonance imaging
November 2017
Jia-Sheng Rao, Zuxiang Liu, Can Zhao et al.
Ketamine is a well-known anesthetic. 'Recreational' use of ketamine common induces psychosis-like symptoms and cognitive impairments. The acute and chronic effects of ketamine on relevant brain circuits have been studied, but the effects of single-dose ketamine administration on the local resting-state functional properties of the brain remain unknown. In this study, we aimed to assess the...
American Journal of Geriatric Psychiatry
November 2017
Duncan George, Verònica Gálvez, Donel Martin et al.
To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-resistant depression. Secondary aims were to examine if repeated treatments were safe and more effective in inducing or prolonging remission than a single treatment. In this double-blind, controlled, multiple-crossover study with a 6-month follow-up (randomized controlled trial [RCT] phase), 16 participants (≥60...
Military Medicine
October 31, 2017
Madeleine Baldwin, Henry Boilini, Georgine Lamvu
7 citations
In the United States, the suicide rate is climbing and was reported at 13 per 100,000, the highest in 28 years. 1 Suicide is now considered as the 10th leading cause of death, and the rate has been increasing every year from 2000 to 2014 among both women and men and in every age group except those 75 and older. 1 The suicide rate among the veteran population is reportedly higher than the...